Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04571658 · ClinicalTrials.gov registry record · NA

NEPTUNE Match Study

A NA study of Focal Segmental Glomerulosclerosis and Minimal Change Disease, sponsored by University of Michigan.

Recruiting
Registry status
NA
Development phase
375
Enrollment target
16
Study locations

NCT04571658 is a NA study of Focal Segmental Glomerulosclerosis and Minimal Change Disease that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 375 participants, above the 217-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (73% higher). The trial reports 16 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04571658, a NA study of Focal Segmental Glomerulosclerosis and Minimal Change Disease, is actively recruiting participants, sponsored by University of Michigan.

RECRUITING
Registry status
NA
Development phase
375 participants
Enrollment target
16
Study locations

Study Summary

NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.

Conditions Studied

Focal Segmental Glomerulosclerosis Minimal Change Disease Membranous Nephropathy Alport Syndrome FSGS MCD Nephrotic Syndrome in Children Minimal Change Nephrotic Syndrome MCD - Minimal Change Disease

Interventions

  • OTHER Communication

Study Locations (16)

Washington

  • Seattle Children's Hospital - Seattle
  • University of Washington Medical Center - Seattle
  • Providence Sacred Heart Medical Center - Spokane

New York

  • Northwell/Cohen's Children's Hospital - New Hyde Park
  • Columbia University Medical Center - New York

Pennsylvania

  • Hospital of the University of Pennsylvania - Philadelphia
  • Temple University - Philadelphia

Georgia

  • Emory University Hospital - Children's Hospital of Atlanta - Atlanta

Illinois

  • John H. Stroger, Jr., Hospital of Cook County - Chicago

Kansas

  • University of Kansas Medical Center - Kansas City

Maryland

  • Johns Hopkins Medicine - Baltimore

Michigan

  • University of Michigan - Ann Arbor

Trial Details

FieldValue
Enrollment Target 375 participants
Start Date 2022-05-02
Est. Completion 2029-06-30
Phase NA

Sponsor

University of Michigan

1,327 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04571658

The ClinicalTrials.gov registry entry for NCT04571658 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 375 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 217-participant average among 19 other Focal Segmental Glomerulosclerosis trials with a reported enrollment target (73% higher). The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Focal Segmental Glomerulosclerosis appearing as the primary indexed condition, and to 1 intervention - of which Communication is the first listed.

NCT04571658 reports 16 study locations spanning 12 distinct geographic areas - top geographies include Washington, New York, Pennsylvania.

Frequently Asked Questions

What is clinical trial NCT04571658 about?

NCT04571658 is a clinical study titled "NEPTUNE Match Study". NEPTUNE Match is an additional opportunity offered to NEPTUNE study participants to prospectively recruit and communicate patient-specific clinical trial matching with kidney patients and their physician investigators.

What is the current status of trial NCT04571658?

This trial is currently recruiting. It is a NA study. The enrollment target is 375 participants. The study started on 2022-05-02. Estimated completion is 2029-06-30.

What conditions does trial NCT04571658 study?

This clinical trial studies the following conditions: Focal Segmental Glomerulosclerosis, Minimal Change Disease, Membranous Nephropathy, Alport Syndrome, FSGS.

What interventions are being tested in trial NCT04571658?

The interventions under investigation include: Communication (OTHER).

Who is sponsoring clinical trial NCT04571658?

This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04571658 being conducted?

This trial has 16 study locations across Georgia, Illinois, Kansas, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Focal Segmental Glomerulosclerosis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Focal Segmental Glomerulosclerosis

All registered trials for this condition

Minimal Change Disease

All registered trials for this condition

Georgia

All trials with a study site in Georgia

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.